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      Dear  Sir: 
  We read with great interest the article on pneumococcal 
serotyping in Laos by Moore and others  1   and the accompa-
nying editorial by Mehta  2   in the September 2010 issue of   The 
American Journal of Tropical Medicine and Hygiene . We  com-
mend Moore on describing the pneumococcal serotype dis-
tribution in this country in Asia, a region with relatively few 
data on pneumococcal serotypes causing invasive disease.  3  
However, we draw different conclusions from the data than 
Mehta did in his editorial, and propose that these data sup-
port the use of currently available pneumococcal conjugate 
vaccines in Asia now, rather than further delays. What is miss-
ing in much of the developing world right now is high-quality 
surveillance rather than high-quality vaccines. 
  An estimated 800,000 children died of pneumococcal dis-
ease in 2000, with much of the burden in Asia.  4   The World 
Health Organization recommends that all countries introduce 
pneumococcal conjugate vaccine into their routine childhood 
immunization systems.  5   Countries that newly introduce pneu-
mococcal conjugate vaccines into their routine childhood 
immunization systems will not introduce the 7-valent pneu-
mococcal conjugate vaccine (PCV7), which is soon to be 
phased out of production, but rather the currently available 
10- or 13-valent pneumococcal conjugate vaccines. Although 
more than 90 pneumococcal serotypes have been identified, a 
recent review article on serotype distribution worldwide found 
that serotypes included in the 10- and 13-valent pneumococ-
cal conjugate vaccine formulations cause at least three-quar-
ters of disease in all regions, including Asia.  3   Indeed, Moore 
reported that while PCV7 includes serotypes causing less than 
half of invasive pneumococcal disease (IPD) in Laos, the 10- 
and 13-valent pneumococcal vaccines include the majority of 
serotypes causing disease (73% and 73%, respectively).  1  
  The editorial’s suggestion that pneumococcal bacteria and 
influenza viruses are similar is incorrect. Although pneumococ-
cal serotypes causing disease in a community can vary a little in 
their individual incidence from year to year, especially if out-
breaks occur, the bacteria do not continually “drift” over time 
like influenza strains; therefore, pneumococcal vaccines do not 
require annual updates. Decreases in invasive pneumococcal dis-
ease caused by serotypes in PCV7 among children of the age tar-
geted for vaccination have been rapid, substantial, and sustained. 
Despite variable increases in rates of IPD caused by serotypes 
not in PCV7, overall reductions in rates of IPD following intro-
duction of PCV7 in children have been consistently observed in 
multiple countries.  6–  8   The editorial suggests that serotypes 1 and 
5 might be selected by use of PCV7; however, increases in dis-
ease caused by these serotypes has not been seen in countries 
that have introduced PCV7 and substantial outbreaks of each 
have been observed in the absence of vaccination.  9   More impor-
tantly, both serotypes 1 and 5 are included in 10- and 13-valent 
vaccines and, as such, vaccination should make these serotypes 
less, not more, likely to cause disease. 
  We agree about the urgent need for ongoing surveillance 
to monitor changes in pneumococcal epidemiology that can 
help policymakers make informed decisions regarding their 
pneumococcal vaccine programs. In interpreting surveillance 
data, the public health impact of vaccines will be best reflected 
by monitoring changes in the overall rate of IPD, rather than 
focusing more narrowly on percent increases in non-vaccine 
types. On the basis of all available data, currently available 
pneumococcal conjugate vaccines cover about three-quarters 
of all the serotypes causing disease in young children. Global 
surveillance for IPD, on the other hand, does not yet cover 
three-quarters of the places where we should have it. 
  Perhaps it is time to shift the focus from expanding the sero-
types in the vaccine to expanding access to the vaccine for chil-
dren in countries like Laos, and assuring that the surveillance 
systems are in place to monitor the vaccine’s effects. Mehta 
states that countries should find “the right pneumococcal vac-
cine for the time and place.” We agree. With 10- and 13-valent 
vaccines available right now through the GAVI Alliance for 
countries like Laos, the data in the paper by Moore suggest 
that the right vaccines are here, and the right time is now. 
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